Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Proteomic identification of Alzheimer's Disease biomarkers

EF 2018-19

Résumé
Alzheimer’s Disease (AD) is a neurodegenerative disease characterized by gradual cognitive decline and deposition of amyloid-beta (A?) plaques and neurofibrillary tangles in the brain. Current clinical practices rely on evaluating clinical symptoms, providing no definitive diagnosis until post-mortem neuropathological confirmation. Additionally, the prevailing biomarkers of AD, A? plaques and tau, cannot reliably resolve disease progression and differential diagnosis. The cerebrospinal fluid (CSF), a proximal fluid to the CNS, offers an ideal reservoir for biomarker discovery, as it reflects biochemical changes in the brain. Preliminary evidence from our laboratory suggests that brain-specific proteins in the CSF, neuropentraxin receptor (NPTXR), A? precursor-like protein 1 (APLP1), and brain-derived neurotrophic factor (BDNF), are biomarkers of AD. I aim to 1) discover additional CSF biomarkers of AD from 60 brain-specific candidate proteins and 2) validate NPTXR, APLP1, and BDNF as biomarkers of AD using a pool of patient CSF samples with matched controls (n=557). I hypothesize that downregulated NPTXR and BDNF levels combined with upregulated APLP1, in addition to other proteins, will create a biomarker pattern that could serve as a robust readout for monitoring AD. I will perform targeted mass spectrometry of 60 candidate proteins in a cohort of control, MCI and AD patient CSF to generate a multivariate prediction panel using machine-learning algorithms. Next, I will leverage existing patient CSF samples, including longitudinally-followed patients and a gradient of AD severities, to validate NPTXR, APLP1, and BDNF for diagnosis and monitoring AD using ELISA. I will conduct correlation analyses of MMSE score and other clinical parameters with protein abundance.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406641
Name
Lim Bryant Bak-Yin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Proteomic identification of Alzheimer's Disease biomarkers
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Biomarker Discovery; Biomarker Validation; Cerebrospinal Fluid; Cognitive Function; Dementia Spectrum; Machine Learning; Mass Spectrometry; Neurodegenerative Diseases; Targeted Proteomics
Abstract
Alzheimer’s Disease (AD) is a neurodegenerative disease characterized by gradual cognitive decline and deposition of amyloid-beta (A?) plaques and neurofibrillary tangles in the brain. Current clinical practices rely on evaluating clinical symptoms, providing no definitive diagnosis until post-mortem neuropathological confirmation. Additionally, the prevailing biomarkers of AD, A? plaques and tau, cannot reliably resolve disease progression and differential diagnosis. The cerebrospinal fluid (CSF), a proximal fluid to the CNS, offers an ideal reservoir for biomarker discovery, as it reflects biochemical changes in the brain. Preliminary evidence from our laboratory suggests that brain-specific proteins in the CSF, neuropentraxin receptor (NPTXR), A? precursor-like protein 1 (APLP1), and brain-derived neurotrophic factor (BDNF), are biomarkers of AD. I aim to 1) discover additional CSF biomarkers of AD from 60 brain-specific candidate proteins and 2) validate NPTXR, APLP1, and BDNF as biomarkers of AD using a pool of patient CSF samples with matched controls (n=557). I hypothesize that downregulated NPTXR and BDNF levels combined with upregulated APLP1, in addition to other proteins, will create a biomarker pattern that could serve as a robust readout for monitoring AD. I will perform targeted mass spectrometry of 60 candidate proteins in a cohort of control, MCI and AD patient CSF to generate a multivariate prediction panel using machine-learning algorithms. Next, I will leverage existing patient CSF samples, including longitudinally-followed patients and a gradient of AD severities, to validate NPTXR, APLP1, and BDNF for diagnosis and monitoring AD using ELISA. I will conduct correlation analyses of MMSE score and other clinical parameters with protein abundance.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lim, Bryant Bak-Yin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~